<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476238</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01026</org_study_id>
    <nct_id>NCT04476238</nct_id>
  </id_info>
  <brief_title>Inosine Energy Expenditure Study</brief_title>
  <acronym>InoBAT</acronym>
  <official_title>Randomized Cross-over Trial to Investigate the Effect of Inosine on Human Energy Expenditure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators want to test whether the intake of the nucleoside inosine increases the human&#xD;
      energy expenditure. Inosine occurs as a metabolic intermediate in the human body and is&#xD;
      sometimes taken as a dietary supplement by athletes.&#xD;
&#xD;
      For this purpose, investigators will measure the basal metabolic rate by indirect&#xD;
      calorimetry. Study participants will then take inosine dissolved in water or placebo and&#xD;
      energy expenditure will be assessed again.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>resting energy expenditure after Inosine</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>resting energy expenditure (REE) assessed by indirect calorimetry after oral intake of two grams of inosine as compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in energy expenditure</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>- Difference in EE between baseline measurement and measurement one hour after administration of inosine or control, respectively, at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Respiratory Quotient</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>- Respiratory quotient (RQ) as an indicator of substrate oxidation one hour after oral intake of two grams of inosine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inosine level</measure>
    <time_frame>0 hours, 1 hour, 2 hours</time_frame>
    <description>Serum inosine levels after ingestion of inosine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Inosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 grams of inosine dissolved in 250 ml of tap water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 ml of tap water only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inosine</intervention_name>
    <description>2 grams of inosine dissolved in 250 ml water taken by mouth</description>
    <arm_group_label>Inosine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>250 ml water taken by mouth</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers&#xD;
&#xD;
          -  BMI between 18-27 kg/m2&#xD;
&#xD;
          -  Age between 18 and 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic concomitant disease states (e.g., renal failure, hepatic dysfunction,&#xD;
             cardiovascular disease, diabetes mellitus),&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  Inability to follow the procedures of the study&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study,&#xD;
&#xD;
          -  Previous enrolment into the current study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons,&#xD;
&#xD;
          -  Thyroid disorders&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthias J Betz, MD</last_name>
    <phone>0041 61 265</phone>
    <phone_ext>2525</phone_ext>
    <email>Matthias.Betz@usb.ch</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Energy expenditure</keyword>
  <keyword>metabolism</keyword>
  <keyword>inosine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

